Identification

Name
Atomoxetine
Accession Number
DB00289  (APRD00614)
Type
Small Molecule
Groups
Approved
Description

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]

Structure
Thumb
Synonyms
  • (-)-Tomoxetine
  • Tomoxetina
  • Tomoxetine
  • Tomoxetinum
Product Ingredients
IngredientUNIICASInChI Key
Atomoxetine hydrochloride57WVB6I2W082248-59-7LUCXVPAZUDVVBT-UNTBIKODSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AtomoxetineCapsule60 mgOralSanis Health Inc2018-01-15Not applicableCanada
AtomoxetineCapsule60 mgOralPro Doc Limitee2012-11-29Not applicableCanada
AtomoxetineCapsule10 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
AtomoxetineCapsule18 mgOralPro Doc Limitee2012-11-29Not applicableCanada
AtomoxetineCapsule40 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
AtomoxetineCapsule100 mgOralSanis Health Inc2018-01-15Not applicableCanada
AtomoxetineCapsule18 mgOralSanis Health Inc2018-01-15Not applicableCanada
AtomoxetineCapsule40 mgOralPro Doc Limitee2012-11-29Not applicableCanada
AtomoxetineCapsule40 mgOralSanis Health Inc2018-01-15Not applicableCanada
AtomoxetineCapsule80 mgOralSanis Health Inc2018-01-15Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atomoxetineCapsule18 mgOralApotex Corporation2011-03-15Not applicableCanada
Apo-atomoxetineCapsule100 mgOralApotex Corporation2011-07-19Not applicableCanada
Apo-atomoxetineCapsule40 mgOralApotex Corporation2011-07-19Not applicableCanada
Apo-atomoxetineCapsule10 mgOralApotex Corporation2011-03-15Not applicableCanada
Apo-atomoxetineCapsule80 mgOralApotex Corporation2011-07-19Not applicableCanada
Apo-atomoxetineCapsule25 mgOralApotex Corporation2011-03-15Not applicableCanada
Apo-atomoxetineCapsule60 mgOralApotex Corporation2011-07-19Not applicableCanada
AtomoxetineCapsule40 mg/1OralNorth Star Rx Llc2018-06-01Not applicableUs
AtomoxetineCapsule18 mg/1OralPrasco, Laboratories2017-05-30Not applicableUs
AtomoxetineCapsule18 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2017-05-30Not applicableUs
International/Other Brands
Attentin / Tomoxetin
Categories
UNII
ASW034S0B8
CAS number
83015-26-3
Weight
Average: 255.3547
Monoisotopic: 255.162314299
Chemical Formula
C17H21NO
InChI Key
VHGCDTVCOLNTBX-QGZVFWFLSA-N
InChI
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
IUPAC Name
methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine
SMILES
CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.

Associated Conditions
Pharmacodynamics

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). Atomoxetine is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in adults and children.

Mechanism of action

The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined through in-vitro studies. Atomoxetine appears to have minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors.

TargetActionsOrganism
ASodium-dependent noradrenaline transporterNot AvailableHuman
USodium-dependent serotonin transporterNot AvailableHuman
USodium-dependent dopamine transporter
binder
Human
UNMDA receptor
blocker
Human
Absorption

Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) have no effect on atomoxetine bioavailability. Absorption is minimally affected by food.

Volume of distribution
  • 0.85 L/kg
Protein binding

At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin.

Metabolism

Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs).

Route of elimination
Not Available
Half life

5 hours

Clearance
  • 0.35 L/hr/kg [after oral administration in adult extensive metabolizers]
  • 0.03 L/hr/kg [administration of atomoxetine to poor metabolizers]
Toxicity

The most commonly reported symptoms accompanying acute and chronic overdoses are somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3(-;-)2549delAEffect Directly StudiedThe presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.Details
Cytochrome P450 2D6CYP2D6*4(A;A)A Allele, homozygoteEffect Directly StudiedThe presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole Gene DeletionEffect Directly StudiedThe presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.Details
Cytochrome P450 2D6CYP2D6*6(-;-) / (-;T)T deletion, homozygoteEffect Directly StudiedThe presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, increased side effects.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.Details

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Atomoxetine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the central neurotoxic activities of Atomoxetine.Experimental
AbediterolAtomoxetine may increase the tachycardic activities of Abediterol.Investigational
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Atomoxetine.Approved, Investigational
AbirateroneThe serum concentration of Atomoxetine can be increased when it is combined with Abiraterone.Approved
AcebutololAtomoxetine may increase the hypertensive activities of Acebutolol.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Atomoxetine.Approved, Investigational
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Atomoxetine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Atomoxetine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Atomoxetine.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Atomoxetine.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Atomoxetine.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Atomoxetine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Atomoxetine.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Atomoxetine.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Atomoxetine.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Atomoxetine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Atomoxetine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Atomoxetine.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Atomoxetine.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Atomoxetine.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Atomoxetine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Atomoxetine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Amikacin.Approved, Investigational, Vet Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Atomoxetine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Atomoxetine.Approved
AmiodaroneThe serum concentration of Atomoxetine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Atomoxetine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Atomoxetine.Approved
AmphetamineAmphetamine may increase the central neurotoxic activities of Atomoxetine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Atomoxetine.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Atomoxetine.Approved, Investigational
AnagrelideAtomoxetine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Atomoxetine.Approved, Investigational
ApalutamideThe serum concentration of Atomoxetine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Atomoxetine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Atomoxetine.Approved, Investigational
AprepitantThe metabolism of Aprepitant can be decreased when combined with Atomoxetine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Atomoxetine.Approved
ArbutamineAtomoxetine may increase the tachycardic activities of Arbutamine.Approved
ArformoterolAtomoxetine may increase the tachycardic activities of Arformoterol.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Atomoxetine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.Approved, Investigational
ArmodafinilThe metabolism of Atomoxetine can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideAtomoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherAtomoxetine may increase the QTc-prolonging activities of Artemether.Approved
AsenapineAtomoxetine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Atomoxetine.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Atomoxetine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Atomoxetine.Approved, Investigational
AtorvastatinThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Atomoxetine.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Atomoxetine.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Atomoxetine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Atomoxetine.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Atomoxetine.Approved
BambuterolAtomoxetine may increase the tachycardic activities of Bambuterol.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Atomoxetine.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Atomoxetine.Approved, Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Atomoxetine.Approved
BenmoxinBenmoxin may increase the central neurotoxic activities of Atomoxetine.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Benzatropine.Approved
BenzphetamineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Atomoxetine.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Atomoxetine.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Atomoxetine.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Atomoxetine.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Atomoxetine.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Atomoxetine.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Atomoxetine.Approved
BitolterolAtomoxetine may increase the tachycardic activities of Bitolterol.Withdrawn
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Atomoxetine.Approved, Investigational
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Atomoxetine.Approved, Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Atomoxetine.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Atomoxetine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atomoxetine.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Atomoxetine.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Atomoxetine.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Atomoxetine.Approved, Investigational
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Atomoxetine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Atomoxetine.Approved, Investigational
BrofaromineBrofaromine may increase the central neurotoxic activities of Atomoxetine.Experimental
BromazepamThe metabolism of Bromazepam can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Atomoxetine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Atomoxetine.Approved
BucindololAtomoxetine may increase the hypertensive activities of Bucindolol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Atomoxetine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Atomoxetine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Atomoxetine can be increased when it is combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Atomoxetine.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Atomoxetine.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Atomoxetine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Atomoxetine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Atomoxetine.Approved, Investigational
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Atomoxetine.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Atomoxetine.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Atomoxetine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Atomoxetine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Atomoxetine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Atomoxetine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Atomoxetine.Approved, Investigational
CaroxazoneCaroxazone may increase the central neurotoxic activities of Atomoxetine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Atomoxetine.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Atomoxetine.Approved, Investigational
CeliprololAtomoxetine may increase the hypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
CeritinibAtomoxetine may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Atomoxetine.Approved, Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Atomoxetine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Atomoxetine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Atomoxetine.Approved
ChloramphenicolThe metabolism of Atomoxetine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Chlorphenamine.Approved
ChlorphentermineAtomoxetine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Atomoxetine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Atomoxetine.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Atomoxetine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Atomoxetine.Approved, Investigational
CimetidineThe metabolism of Atomoxetine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Atomoxetine can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ciprofloxacin.Approved, Investigational
CisaprideAtomoxetine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramAtomoxetine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Atomoxetine.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Clemastine.Approved, Investigational
ClenbuterolAtomoxetine may increase the hypertensive activities of Clenbuterol.Approved, Investigational, Vet Approved
ClindamycinThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Atomoxetine.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Atomoxetine.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Atomoxetine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Atomoxetine.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Atomoxetine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Atomoxetine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Atomoxetine.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Atomoxetine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Atomoxetine.Approved, Illicit
ClozapineThe metabolism of Clozapine can be decreased when combined with Atomoxetine.Approved
CobicistatThe serum concentration of Atomoxetine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Atomoxetine.Approved, Investigational
CocaineThe serum concentration of Atomoxetine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Atomoxetine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Atomoxetine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Atomoxetine.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Atomoxetine.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Atomoxetine.Approved, Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Atomoxetine.Approved, Investigational
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Atomoxetine.Approved
CurcuminThe metabolism of Atomoxetine can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Atomoxetine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Atomoxetine.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Atomoxetine.Approved, Investigational
DabrafenibThe serum concentration of Atomoxetine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Atomoxetine.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Atomoxetine.Approved, Investigational
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Atomoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Atomoxetine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Atomoxetine.Approved, Investigational
DarunavirThe serum concentration of Atomoxetine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Atomoxetine.Approved
DasatinibThe metabolism of Dasatinib can be decreased when combined with Atomoxetine.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Atomoxetine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Atomoxetine.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Atomoxetine.Approved, Investigational
DelamanidThe metabolism of Delamanid can be decreased when combined with Atomoxetine.Approved, Investigational
DelavirdineThe serum concentration of Atomoxetine can be increased when it is combined with Delavirdine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Atomoxetine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Desvenlafaxine.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Atomoxetine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atomoxetine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Atomoxetine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Atomoxetine.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Atomoxetine.Approved, Illicit
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational, Vet Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Atomoxetine.Approved
DiethylpropionThe risk or severity of hypertension can be increased when Atomoxetine is combined with Diethylpropion.Approved, Illicit
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Atomoxetine.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Atomoxetine.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Atomoxetine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Atomoxetine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Atomoxetine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Atomoxetine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Atomoxetine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Atomoxetine.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Atomoxetine.Approved, Investigational
DipivefrinAtomoxetine may increase the tachycardic activities of Dipivefrin.Approved
DisopyramideAtomoxetine may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Atomoxetine.Approved
DobutamineAtomoxetine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Atomoxetine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Atomoxetine.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Atomoxetine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Atomoxetine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Atomoxetine.Approved
DopamineAtomoxetine may increase the hypertensive activities of Dopamine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Atomoxetine.Approved
DosulepinThe serum concentration of Atomoxetine can be increased when it is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Dotarizine.Investigational
DoxepinThe metabolism of Doxepin can be decreased when combined with Atomoxetine.Approved, Investigational
DoxofyllineAtomoxetine may increase the tachycardic activities of Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atomoxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Atomoxetine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Atomoxetine.Approved, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Atomoxetine.Approved, Illicit
DronedaroneAtomoxetine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolAtomoxetine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxidopaAtomoxetine may increase the tachycardic activities of Droxidopa.Approved, Investigational
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Atomoxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Atomoxetine.Approved, Investigational
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Atomoxetine.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Atomoxetine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Atomoxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Atomoxetine.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Atomoxetine.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Atomoxetine.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Atomoxetine.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Atomoxetine.Investigational
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Atomoxetine.Approved
EpanololAtomoxetine may increase the hypertensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Eperisone.Approved, Investigational
EphedraAtomoxetine may increase the tachycardic activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineAtomoxetine may increase the hypertensive activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Atomoxetine.Approved, Investigational
EpinephrineAtomoxetine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Atomoxetine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Atomoxetine.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Atomoxetine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Atomoxetine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Atomoxetine.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
EscitalopramAtomoxetine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Atomoxetine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Atomoxetine.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Atomoxetine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Atomoxetine.Approved, Illicit
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Atomoxetine.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Atomoxetine.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Atomoxetine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Atomoxetine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Atomoxetine.Approved, Investigational
EtafedrineAtomoxetine may increase the tachycardic activities of Etafedrine.Approved
EthanolAtomoxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Atomoxetine.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Atomoxetine.Approved, Illicit
EtilefrineAtomoxetine may increase the hypertensive activities of Etilefrine.Withdrawn
EtizolamThe metabolism of Etizolam can be decreased when combined with Atomoxetine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Atomoxetine.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Atomoxetine.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Atomoxetine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Atomoxetine.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Atomoxetine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Atomoxetine.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Atomoxetine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Famotidine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Atomoxetine.Approved
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Atomoxetine.Approved
FenoterolAtomoxetine may increase the hypertensive activities of Fenoterol.Approved, Investigational
FenozoloneAtomoxetine may increase the hypertensive activities of Fenozolone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Atomoxetine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Atomoxetine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Atomoxetine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Atomoxetine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Flibanserin.Approved, Investigational
FluconazoleThe metabolism of Atomoxetine can be decreased when combined with Fluconazole.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Atomoxetine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Atomoxetine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Atomoxetine.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Atomoxetine.Approved, Investigational
FluoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolAtomoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Atomoxetine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Atomoxetine.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Atomoxetine.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Atomoxetine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Atomoxetine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Fluvoxamine.Approved, Investigational
FormoterolAtomoxetine may increase the tachycardic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Atomoxetine.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Atomoxetine.Approved
FosphenytoinThe metabolism of Atomoxetine can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Atomoxetine.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Atomoxetine.Approved, Investigational
FurazolidoneFurazolidone may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Atomoxetine.Approved, Investigational
Gadobenic acidAtomoxetine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Atomoxetine.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Atomoxetine.Approved, Investigational
GemfibrozilThe metabolism of Atomoxetine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAtomoxetine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinAtomoxetine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Atomoxetine.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Atomoxetine.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Atomoxetine.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Atomoxetine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Atomoxetine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Atomoxetine.Approved, Vet Approved
HarmalineHarmaline may increase the central neurotoxic activities of Atomoxetine.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Atomoxetine.Approved
HexoprenalineAtomoxetine may increase the tachycardic activities of Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the central neurotoxic activities of Atomoxetine.Experimental
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Atomoxetine.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Atomoxetine.Approved, Illicit
HydroxyamphetamineAtomoxetine may increase the hypertensive activities of Hydroxyamphetamine.Approved
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Atomoxetine.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Atomoxetine.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ibandronate.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Atomoxetine.Approved
IbutilideAtomoxetine may increase the QTc-prolonging activities of Ibutilide.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Atomoxetine.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Atomoxetine.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Atomoxetine resulting in a loss in efficacy.Approved
IloperidoneAtomoxetine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Atomoxetine.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Atomoxetine.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Atomoxetine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Atomoxetine.Approved, Investigational
IndacaterolAtomoxetine may increase the tachycardic activities of Indacaterol.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Atomoxetine.Approved
IndinavirThe metabolism of Indinavir can be decreased when combined with Atomoxetine.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Atomoxetine.Approved, Withdrawn
IproclozideIproclozide may increase the central neurotoxic activities of Atomoxetine.Withdrawn
IproniazidIproniazid may increase the central neurotoxic activities of Atomoxetine.Withdrawn
IsavuconazoleThe metabolism of Isavuconazole can be decreased when combined with Atomoxetine.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Atomoxetine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Atomoxetine.Approved
IsoetarineAtomoxetine may increase the tachycardic activities of Isoetarine.Approved
IsoniazidThe metabolism of Atomoxetine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineAtomoxetine may increase the hypertensive activities of Isoprenaline.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atomoxetine.Approved
IsoxsuprineAtomoxetine may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Atomoxetine.Approved, Investigational
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Atomoxetine.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Atomoxetine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Atomoxetine.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Atomoxetine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Atomoxetine.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Atomoxetine.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Atomoxetine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Atomoxetine.Approved, Investigational
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Atomoxetine.Approved, Investigational
LabetalolThe risk or severity of hypertension can be increased when Atomoxetine is combined with Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Atomoxetine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Atomoxetine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Atomoxetine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Atomoxetine.Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Atomoxetine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Atomoxetine.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Atomoxetine.Approved, Investigational
LeuprolideAtomoxetine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Atomoxetine.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Atomoxetine.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Atomoxetine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Atomoxetine.Approved
LevofloxacinAtomoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Atomoxetine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Atomoxetine.Approved, Investigational
LevosalbutamolAtomoxetine may increase the tachycardic activities of Levosalbutamol.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Atomoxetine.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Atomoxetine.Approved, Investigational
LobeglitazoneThe metabolism of Atomoxetine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe metabolism of Lofexidine can be decreased when combined with Atomoxetine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Atomoxetine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Atomoxetine.Approved, Investigational
LopinavirThe serum concentration of Atomoxetine can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Loratadine.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Atomoxetine.Approved
LorpiprazoleThe metabolism of Lorpiprazole can be decreased when combined with Atomoxetine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Atomoxetine.Approved, Investigational
LuliconazoleThe serum concentration of Atomoxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Atomoxetine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineAtomoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Atomoxetine.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Atomoxetine.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Atomoxetine.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Atomoxetine.Approved
Magnesium carbonateThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Atomoxetine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Atomoxetine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Atomoxetine.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Atomoxetine.Approved, Investigational
MebanazineMebanazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Atomoxetine.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Atomoxetine.Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Atomoxetine.Experimental, Investigational
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Atomoxetine.Approved, Investigational
MefenorexAtomoxetine may increase the hypertensive activities of Mefenorex.Experimental
MefloquineThe metabolism of Mefloquine can be decreased when combined with Atomoxetine.Approved, Investigational
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Atomoxetine.Approved, Vet Approved
MephentermineAtomoxetine may increase the hypertensive activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Atomoxetine.Investigational, Withdrawn
MepyramineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Mepyramine.Approved, Vet Approved
MequitazineThe metabolism of Mequitazine can be decreased when combined with Atomoxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Atomoxetine.Approved, Investigational
MetaraminolAtomoxetine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Atomoxetine.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Atomoxetine.Approved
MethamphetamineAtomoxetine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Atomoxetine.Illicit, Withdrawn
MethotrimeprazineThe serum concentration of Atomoxetine can be increased when it is combined with Methotrimeprazine.Approved, Investigational
MethoxamineAtomoxetine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Atomoxetine.Approved
Methylene blueMethylene blue may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Atomoxetine.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Atomoxetine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Atomoxetine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Atomoxetine.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Metoclopramide.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Atomoxetine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Atomoxetine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Atomoxetine.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Atomoxetine.Approved, Investigational
MidazolamThe metabolism of Midazolam can be decreased when combined with Atomoxetine.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Atomoxetine.Approved
MidodrineAtomoxetine may increase the hypertensive activities of Midodrine.Approved
MidostaurinThe serum concentration of Atomoxetine can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Atomoxetine.Approved, Investigational
MinaprineMinaprine may increase the central neurotoxic activities of Atomoxetine.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Atomoxetine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Atomoxetine.Approved
MoclobemideMoclobemide may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Atomoxetine.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Atomoxetine.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Atomoxetine.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Atomoxetine.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Atomoxetine.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atomoxetine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Atomoxetine.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Atomoxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Atomoxetine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Atomoxetine.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Atomoxetine.Approved
NeomycinThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Neomycin.Approved, Vet Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Atomoxetine.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Atomoxetine.Approved, Investigational
NevirapineThe metabolism of Nevirapine can be decreased when combined with Atomoxetine.Approved
NialamideNialamide may increase the central neurotoxic activities of Atomoxetine.Withdrawn
NicardipineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Atomoxetine.Approved, Investigational
NilotinibAtomoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Atomoxetine.Approved, Investigational
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Atomoxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
NorepinephrineAtomoxetine may increase the hypertensive activities of Norepinephrine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Atomoxetine.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Atomoxetine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Atomoxetine.Approved
NylidrinThe risk or severity of hypertension can be increased when Atomoxetine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the central neurotoxic activities of Atomoxetine.Withdrawn
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Atomoxetine.Investigational
OfloxacinAtomoxetine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Atomoxetine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Atomoxetine.Approved
OlodaterolAtomoxetine may increase the tachycardic activities of Olodaterol.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Atomoxetine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ondansetron.Approved
OpiumThe metabolism of Opium can be decreased when combined with Atomoxetine.Approved, Illicit
OrciprenalineAtomoxetine may increase the hypertensive activities of Orciprenaline.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Atomoxetine.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Atomoxetine.Approved, Investigational
OxazepamThe metabolism of Oxazepam can be decreased when combined with Atomoxetine.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Atomoxetine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Atomoxetine.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Atomoxetine.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Atomoxetine.Approved, Vet Approved
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Atomoxetine.Approved, Investigational
PaliperidoneAtomoxetine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Atomoxetine.Approved, Investigational
PanobinostatThe serum concentration of Atomoxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Atomoxetine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Atomoxetine.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Atomoxetine.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Atomoxetine.Approved
PargylinePargyline may increase the central neurotoxic activities of Atomoxetine.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Atomoxetine.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Atomoxetine.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Paromomycin.Approved, Investigational
ParoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Atomoxetine.Approved
Peginterferon alfa-2bThe serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Atomoxetine.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Atomoxetine.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Atomoxetine.Approved
PerflutrenAtomoxetine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Atomoxetine.Approved, Investigational, Vet Approved, Withdrawn
PermethrinThe metabolism of Permethrin can be decreased when combined with Atomoxetine.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Atomoxetine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Atomoxetine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Atomoxetine.Approved
PF-00610355Atomoxetine may increase the tachycardic activities of PF-00610355.Investigational
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Atomoxetine.Withdrawn
PhenelzinePhenelzine may increase the central neurotoxic activities of Atomoxetine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pheniramine.Approved
PhenmetrazineAtomoxetine may increase the hypertensive activities of Phenmetrazine.Approved, Illicit
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Atomoxetine.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Atomoxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Atomoxetine.Approved, Investigational
PhentermineAtomoxetine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhenylephrineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Phenylephrine.Approved
PhenylpropanolamineAtomoxetine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Atomoxetine can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Atomoxetine.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Atomoxetine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Atomoxetine.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Atomoxetine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Atomoxetine.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Atomoxetine.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Atomoxetine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Atomoxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Atomoxetine.Approved, Investigational
PirbuterolAtomoxetine may increase the tachycardic activities of Pirbuterol.Approved
PirlindolePirlindole may increase the central neurotoxic activities of Atomoxetine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atomoxetine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Atomoxetine.Approved, Investigational
PivhydrazinePivhydrazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
PodofiloxThe metabolism of Podofilox can be decreased when combined with Atomoxetine.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Atomoxetine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Atomoxetine.Approved, Investigational
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
PramipexoleAtomoxetine may increase the sedative activities of Pramipexole.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Atomoxetine.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Atomoxetine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Atomoxetine.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Atomoxetine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Atomoxetine.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Atomoxetine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolAtomoxetine may increase the hypertensive activities of Prenalterol.Experimental
PrimaquineThe metabolism of Primaquine can be decreased when combined with Atomoxetine.Approved
ProcainamideAtomoxetine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational
ProcaterolAtomoxetine may increase the hypertensive activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Atomoxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Atomoxetine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Atomoxetine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Atomoxetine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Atomoxetine.Approved, Investigational
PropafenoneThe serum concentration of Atomoxetine can be increased when it is combined with Propafenone.Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Atomoxetine.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
ProtokylolAtomoxetine may increase the tachycardic activities of Protokylol.Approved, Vet Approved
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Atomoxetine.Approved
PseudoephedrineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Pyrantel.Approved, Vet Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Atomoxetine.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Atomoxetine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Quetiapine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Atomoxetine.Approved, Investigational
QuinidineThe serum concentration of Atomoxetine can be increased when it is combined with Quinidine.Approved, Investigational
QuinineAtomoxetine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Atomoxetine.Approved, Investigational
RacepinephrineAtomoxetine may increase the hypertensive activities of Racepinephrine.Approved
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Atomoxetine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Atomoxetine.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Atomoxetine.Approved, Investigational
RasagilineRasagiline may increase the central neurotoxic activities of Atomoxetine.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Atomoxetine.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Atomoxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Atomoxetine.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Atomoxetine.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Atomoxetine.Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Atomoxetine.Approved
RifabutinThe metabolism of Rifabutin can be decreased when combined with Atomoxetine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Atomoxetine.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Atomoxetine.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Atomoxetine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Atomoxetine.Approved, Investigational
RitodrineAtomoxetine may increase the hypertensive activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Atomoxetine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Atomoxetine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Rizatriptan.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Atomoxetine.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Atomoxetine.Approved, Investigational
RopiniroleAtomoxetine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Atomoxetine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Atomoxetine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Atomoxetine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Atomoxetine.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Atomoxetine.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Atomoxetine.Approved, Investigational
SafrazineSafrazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
SalbutamolAtomoxetine may increase the tachycardic activities of Salbutamol.Approved, Vet Approved
SalmeterolAtomoxetine may increase the tachycardic activities of Salmeterol.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Atomoxetine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atomoxetine.Approved, Investigational
SelegilineSelegiline may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Atomoxetine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Atomoxetine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Atomoxetine.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Atomoxetine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Atomoxetine.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Atomoxetine.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Atomoxetine.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Atomoxetine.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Atomoxetine.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Atomoxetine.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Atomoxetine.Approved, Investigational
SotalolAtomoxetine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Atomoxetine.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Atomoxetine.Approved
StiripentolThe serum concentration of Atomoxetine can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Atomoxetine.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Atomoxetine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Atomoxetine.Approved
SulfisoxazoleAtomoxetine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Atomoxetine.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Atomoxetine.Approved, Investigational
SynephrineAtomoxetine may increase the hypertensive activities of Synephrine.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Atomoxetine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Atomoxetine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Atomoxetine.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Atomoxetine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Atomoxetine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Atomoxetine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Atomoxetine.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Atomoxetine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Atomoxetine.Experimental
TegaserodThe metabolism of Tegaserod can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Atomoxetine.Approved, Withdrawn
TelavancinAtomoxetine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Atomoxetine.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Atomoxetine.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Atomoxetine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Atomoxetine.Approved
TerbinafineThe serum concentration of Atomoxetine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineAtomoxetine may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Atomoxetine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Atomoxetine.Experimental
TerodilineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Terodiline.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Atomoxetine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Atomoxetine.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Atomoxetine.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Atomoxetine.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Atomoxetine.Approved, Investigational
TetrabenazineAtomoxetine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Atomoxetine.Investigational
TetryzolineAtomoxetine may increase the hypertensive activities of Tetryzoline.Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Atomoxetine.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Atomoxetine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Atomoxetine.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Atomoxetine.Approved, Investigational
TiagabineThe metabolism of Tiagabine can be decreased when combined with Atomoxetine.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Atomoxetine.Approved
TiclopidineThe metabolism of Atomoxetine can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Atomoxetine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Atomoxetine.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Atomoxetine.Approved
TipranavirThe serum concentration of Atomoxetine can be increased when it is combined with Tipranavir.Approved, Investigational
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Atomoxetine.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Atomoxetine.Approved, Investigational
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Atomoxetine.Approved, Investigational
ToloxatoneToloxatone may increase the central neurotoxic activities of Atomoxetine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Atomoxetine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atomoxetine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Atomoxetine.Approved
ToremifeneAtomoxetine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Atomoxetine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Atomoxetine.Approved, Investigational
TramazolineAtomoxetine may increase the hypertensive activities of Tramazoline.Investigational
TranylcypromineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Atomoxetine.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Atomoxetine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Atomoxetine.Approved, Investigational, Nutraceutical
TretoquinolAtomoxetine may increase the hypertensive activities of Tretoquinol.Experimental
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Atomoxetine.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Atomoxetine.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Trimethadione.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Atomoxetine.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Atomoxetine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Atomoxetine.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Atomoxetine.Approved
TyramineAtomoxetine may increase the hypertensive activities of Tyramine.Investigational, Nutraceutical
UdenafilThe metabolism of Udenafil can be decreased when combined with Atomoxetine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Atomoxetine.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Atomoxetine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Atomoxetine.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Valproic Acid.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Vancomycin.Approved
VandetanibAtomoxetine may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Atomoxetine.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Atomoxetine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Vecuronium.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Atomoxetine.Approved, Investigational
VemurafenibAtomoxetine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Atomoxetine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Venlafaxine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Atomoxetine.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Atomoxetine.Investigational
VilanterolAtomoxetine may increase the tachycardic activities of Vilanterol.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Atomoxetine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Atomoxetine.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Atomoxetine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Atomoxetine.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Atomoxetine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Atomoxetine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Atomoxetine.Approved, Investigational
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Atomoxetine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Atomoxetine.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Atomoxetine.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Atomoxetine.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Atomoxetine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Atomoxetine.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Atomoxetine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
ZiprasidoneAtomoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Zolmitriptan.Approved, Investigational
ZolpidemAtomoxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Atomoxetine.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Atomoxetine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Atomoxetine.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Atomoxetine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Atomoxetine.Approved, Investigational
Food Interactions
  • In the presence of food, the absorption rate is reduced, without the quantity absorbed being affected.
  • Take without regard to meals.

References

Synthesis Reference

Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei, "Processes for the preparation of atomoxetine hydrochloride." U.S. Patent US20060211772, issued September 21, 2006.

US20060211772
General References
  1. Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. [PubMed:16649828]
  2. Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. [PubMed:16555170]
  3. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. [PubMed:16259536]
  4. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. [PubMed:16113620]
  5. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. [PubMed:17388708]
  6. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049]
  7. Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205-22. [PubMed:14717619]
  8. Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152. [PubMed:19785510]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153]
External Links
Human Metabolome Database
HMDB0014434
KEGG Drug
D07473
PubChem Compound
54841
PubChem Substance
46506160
ChemSpider
49516
BindingDB
50366567
ChEBI
127342
ChEMBL
CHEMBL641
Therapeutic Targets Database
DAP000721
PharmGKB
PA134688071
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Atomoxetine
ATC Codes
N06BA09 — Atomoxetine
AHFS Codes
  • 28:92.00 — Miscellaneous Central Nervous System Agents
FDA label
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
0RecruitingTreatmentParkinson's Disease, Idiopathic1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedBasic ScienceChanges in Striatal [11C]ORM-13070 Binding1
1CompletedBasic ScienceDependence, Cocaine1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
1CompletedTreatmentCocaine-Related Disorders1
1CompletedTreatmentContinuous Methamphetamine Dependence / Methamphetamine Dependence in Remission1
1TerminatedBasic ScienceAlcohol Craving / Emotional Instability1
1TerminatedBasic ScienceAlcohol Sensitivity / Alcohol-induced Cue-craving1
1TerminatedTreatmentMethamphetamine Abuse / Methamphetamine Dependence1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
1, 2CompletedBasic ScienceAttention Deficit Disorder With Hyperactivity (ADHD)1
1, 2CompletedTreatmentMethamphetamine Dependence1
1, 2CompletedTreatmentObstructive Sleep Apnea (OSA)1
1, 2CompletedTreatmentSchizophrenic Disorders1
1, 2CompletedTreatmentStress1
1, 2CompletedTreatmentStress, Physiological1
1, 2SuspendedTreatmentNicotine Dependence1
2Active Not RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Deficient Emotional Self-Regulation (DESR)1
2CompletedBasic ScienceMild Cognitive Impairment (MCI)1
2CompletedTreatmentAtomoxetine Hydrochloride / Placebos1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)3
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Attention-Deficit/Hyperactivity Disorder1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Substance Use Disorder (SUD)1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity / Cocaine-Related Disorders1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity / Marijuana Abuse2
2CompletedTreatmentAttention-Deficit/Hyperactivity Disorder1
2CompletedTreatmentCannabis Dependence1
2CompletedTreatmentChorea / Huntington's Disease (HD)1
2CompletedTreatmentCognition / Schizophrenic Disorders / Smoking1
2CompletedTreatmentCognitive Impairments / Parkinson's Disease (PD)1
2CompletedTreatmentDisseminated Sclerosis / Memory Disorders1
2CompletedTreatmentOpiate Dependence / Stimulant Dependence1
2CompletedTreatmentSubstance Abuse1
2CompletedTreatmentSyncope, Vasovagal1
2RecruitingTreatmentAdult Attention Deficit Hyperactivity Disorder (ADHD)1
2RecruitingTreatmentNeurogenic Orthostatic Hypotension1
2RecruitingTreatmentSyncope, Vasovagal1
2TerminatedTreatmentCognition Disorders / Memory Disorders / Schizophrenic Disorders1
2WithdrawnTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
2, 3CompletedTreatmentAlzheimer's Disease (AD)1
2, 3CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
2, 3CompletedTreatmentGeneralized Social Phobia1
3Active Not RecruitingTreatmentAttention Deficit Disorder With Hyperactivity1
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity3
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)18
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Oppositional Defiant Disorder2
3CompletedTreatmentAttention-Deficit/Hyperactivity Disorder1
3CompletedTreatmentAutism, Early Infantile1
3Enrolling by InvitationTreatmentAutonomic Nervous System Diseases / Dopamine Beta-Hydroxylase Deficiency / Idiopathic orthostatic hypotension / Orthostatic Intolerance1
3Unknown StatusTreatmentAttention Deficit Disorder (ADD) / Attention Deficit Disorder With Hyperactivity (ADHD) / Fetal Alcohol Syndrome (FAS)2
3WithdrawnTreatmentCancers / Cognitive Late Effects1
4CompletedNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)1
4CompletedNot AvailableBinge Eating Disorder (BED)1
4CompletedNot AvailableInjuries, Whiplash1
4CompletedDiagnosticAttention Deficit Disorder With Hyperactivity (ADHD)1
4CompletedTreatmentADHD NOS2
4CompletedTreatmentAsperger's Disorder / Attention Deficit Disorder With Hyperactivity (ADHD) / Autism, Early Infantile / Pervasive Development Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity3
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)16
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Comorbid Alcohol Abuse1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Comorbid Social Anxiety Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Dyslexia2
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Oppositional Defiant Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Reading Disability1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Reading Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Sleeplessness1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity / Autistic Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity / Substance-Related Disorders1
4CompletedTreatmentAttention-Deficit/Hyperactivity Disorder2
4CompletedTreatmentAttention-Deficit/Hyperactivity Disorder / Comorbid Dyslexia1
4CompletedTreatmentCognition in Schizophrenia1
4CompletedTreatmentDepressive Disorders / Parkinson's Disease (PD)1
4CompletedTreatmentDepressive Symptoms1
4CompletedTreatmentExecutive Dysfunction1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders1
4RecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
4RecruitingTreatmentAttention-Deficit/Hyperactivity Disorder1
4RecruitingTreatmentNeurogenic Orthostatic Hypotension1
4TerminatedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)2
4TerminatedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Cannabis Abuse1
4Unknown StatusNot AvailableAttention Deficit Disorder (ADD) / Attention Deficit Disorders With Hyperactivity / Attention Deficit/Hyperactivity Disorder1
4Unknown StatusBasic ScienceAttention Deficit Disorder With Hyperactivity (ADHD)1
4Unknown StatusTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Sleeplessness1
4Unknown StatusTreatmentParkinson's Disease (PD)1
4WithdrawnTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Substance Use Disorder (SUD)1
Not AvailableCompletedNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableCompletedNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD) / Cerebrovascular Accidents / Transient Ischaemic Attack (TIA)1
Not AvailableCompletedTreatmentAddictions1
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)2
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Substance Abuse1
Not AvailableCompletedTreatmentCognitive Impairments / Menopause1
Not AvailableCompletedTreatmentParkinson's Disease (PD)1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedTreatmentTraumatic Brain Injury (TBI)1
Not AvailableEnrolling by InvitationNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableRecruitingNot AvailableAnorexia Nervosa (AN) / Attention Deficit Disorder With Hyperactivity (ADHD) / Depression1
Not AvailableRecruitingNot AvailableAttention Deficit Disorder With Hyperactivity1
Not AvailableRecruitingNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)2
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)3
Not AvailableTerminatedTreatmentDependence, Cocaine / Opiate Dependence1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
Packagers
  • Atlantic Biologicals Corporation
  • Cardinal Health
  • Eli Lilly & Co.
  • Lake Erie Medical and Surgical Supply
  • Lilly Del Caribe Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Remedy Repack
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral60 mg/1
CapsuleOral80 mg/1
CapsuleOral10 mg
CapsuleOral100 mg
CapsuleOral18 mg/1
CapsuleOral18 mg
CapsuleOral25 mg
CapsuleOral40 mg/1
CapsuleOral40 mg
CapsuleOral60 mg
CapsuleOral80 mg
KitOral
Prices
Unit descriptionCostUnit
Strattera 80 mg capsule6.94USD capsule
Strattera 100 mg capsule6.83USD capsule
Strattera 40 mg capsule6.43USD capsule
Strattera 60 mg capsule6.43USD capsule
Strattera 18 mg capsule6.03USD capsule
Strattera 25 mg capsule5.85USD capsule
Strattera 10 mg capsule5.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2209735No2002-10-012016-01-04Canada
US5658590Yes1997-05-262017-05-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility27.8 mg/mLNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0039 mg/mLALOGPS
logP3.95ALOGPS
logP3.81ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity79.44 m3·mol-1ChemAxon
Polarizability29.79 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.964
Caco-2 permeable+0.852
P-glycoprotein substrateSubstrate0.6133
P-glycoprotein inhibitor IInhibitor0.7771
P-glycoprotein inhibitor IINon-inhibitor0.8003
Renal organic cation transporterInhibitor0.5929
CYP450 2C9 substrateNon-substrate0.7443
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6216
CYP450 1A2 substrateInhibitor0.9324
CYP450 2C9 inhibitorNon-inhibitor0.957
CYP450 2D6 inhibitorInhibitor0.9037
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8122
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7371
Ames testNon AMES toxic0.7738
CarcinogenicityNon-carcinogens0.8493
BiodegradationNot ready biodegradable0.8013
Rat acute toxicity2.5166 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7132
hERG inhibition (predictor II)Inhibitor0.7974
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-456e1257123470a131c2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0190000000-0f4cf059747adb026b96
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-ecaeebd63dc195659e57
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6da1a9a3edfed770c2cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00xs-0900000000-d71f5b857319380ce595
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01bc-2900000000-37eb3191934e545cc338
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014l-6900000000-6be893f7d4702639eac2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0190000000-c2030f3f981d83eacf57
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0190000000-3c27da7fa8c958a76be1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-133c9cb2f2383aa0fe8a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00r5-1900000000-b68a2013855cb02e4512
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01bd-1900000000-c4fd6863785e44cc724e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014l-3900000000-4529fcb6c89f3acafac9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-06348bdc8d24fed52e75
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0690000000-494128ae0f3b90b415b3

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Toluenes / Aralkylamines / Alkyl aryl ethers / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Toluene / Aralkylamine / Monocyclic benzene moiety / Secondary aliphatic amine / Ether / Secondary amine / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, secondary amino compound, toluenes (CHEBI:127342)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75. [PubMed:12456942]
  2. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. [PubMed:12523874]
  3. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003 Jan 15;53(2):112-20. [PubMed:12547466]
  4. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. [PubMed:12862507]
  5. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30-5. [PubMed:14709944]
  6. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548]
  7. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004 Oct;8(2):45-52. [PubMed:15801334]
  8. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153]
  10. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. [PubMed:12431845]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Blocker
General Function
Voltage-gated cation channel activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...

Components:
References
  1. Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Fohr KJ: Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010 May;160(2):283-91. doi: 10.1111/j.1476-5381.2010.00707.x. [PubMed:20423340]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049]
  2. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW: Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2004 Feb;308(2):410-8. doi: 10.1124/jpet.103.058727. Epub 2003 Nov 10. [PubMed:14610241]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW: Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2004 Feb;308(2):410-8. doi: 10.1124/jpet.103.058727. Epub 2003 Nov 10. [PubMed:14610241]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:38